UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038432
Receipt number R000043792
Scientific Title Bariatric surgery vs intensive medical therapy in mildly obese Japanese patients with early onset type 2 diabetes mellitus
Date of disclosure of the study information 2019/11/01
Last modified on 2020/04/29 14:30:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Bariatric surgery vs intensive medical therapy in mildly obese Japanese patients
with early onset type 2 diabetes mellitus

Acronym

Bariatric surgery vs intensive medical therapy in mildly obese Japanese patients
with early onset T2DM

Scientific Title

Bariatric surgery vs intensive medical therapy in mildly obese Japanese patients
with early onset type 2 diabetes mellitus

Scientific Title:Acronym

Bariatric surgery vs intensive medical therapy in mildly obese Japanese patients
with early onset T2DM

Region

Japan


Condition

Condition

Obesity, type 2 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism Gastrointestinal surgery Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study will be the first RCT from Japan involving young-onset T2DM with mild obesity. We will determine the relative effectiveness of bariattric surgery in reducing diabetes and CVD risk factor. Best medical management (BMM) will include best available lifestyle modification focusing on weight loss and pharmacologic treatment for diabetes and other CVD risk factors.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary outcome will be assessed at 1 year, and will be a success rate of patients with HbA1c less than 6.5% without diabetes medication.

Key secondary outcomes

1. Changes in weight and BMI, waist circumference, HbA1c, fasting glucose, fasting insulin, systolic blood
pressure, diastolic blood pressure, lipid profile (serum total cholesterol, LDL cholesterol, HDL cholesterol, and
triglycerides)
2. Changes in urine microalbumin/creatinine ratio and resolution of co-morbid renal function illness.
3. Use of medications (as measured by dosages and cost)
4. Total cost of diabetes- and CVD-related health care
5. Measures from three surveys: Quality of life (SF-36). The surveys will be collected at the baseline, 6 months,
and 12 months.
6. Mortality
7. Cardiovascular events (myocardial infarction, stroke, other serious CVD)
8. Complications from surgery


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG-DJB)

Interventions/Control_2

Best medical management focusing on lifestyle modification and pharmacologic treatment

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit

50 years-old >

Gender

Male and Female

Key inclusion criteria

1) Diagnosed with T2DM at the age of younger than 40 years old. 2) Under the active care of a doctor for at least 6 months prior to enrollment, and HbA1c more than 8%.0 % < HbA1c. 3) Duration of T2DM less than 10 years from diagnosis. 4) BMI 27.5-34.9 kg/m2 at eligibility visit. 5) Willingness to accept random assignment to either treatment group. 6) Willingness to comply with the follow-up protocol. 7) Written informed consent.

Key exclusion criteria

1) Cardiovascular event in the past 6 months. 2) Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease. 3) Cardiac stress test indicating that surgery would not be safe. 4) Pulmonary embolus or thrombophlebitis in the past 6 months. 5) Cancer of any kind unless documented to be disease-free for 5 years. 6) Significant anemia (hemoglobin 1.0 g or more below normal range) or history of coagulopathy. 7) Serum creatinine less than 1.5 mg/dl. 8) Serum total bilirubin greater than the upper limit of normal, or alkaline phosphatase or ALT greater than twice the upper limit of normal. 9) History of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or colon resection. 10) Gastric or duodenal ulcer in the past 6 months. 11) History of intra-abdominal sepsis. 12) Self-reported HIV-positive status, active tuberculosis, active malaria, chronic hepatitis B or C, cirrhosis, or inflammatory bowel disease. 13) Currently pregnant or nursing, or planning to become pregnant in the next 2 years. 14) History of alcohol or drug dependency in the past 5 years. 15) Active psychosocial or psychiatric problem that is likely to interfere with adherence to the protocol. 16) Presence of any chronic or debilitating disease that would make adherence to the protocol difficult. 17) 12-lead EKG indicating that surgery would not be safe. 18) Serum fasting c-peptide less than 1.0 ng/ml. 19) Exclusions may also be made at the discretion of the attending physician.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Yosuke
Middle name
Last name Seki

Organization

Yotsuya Medical Cube

Division name

Weight Loss and Metabolic Surgery Center

Zip code

102-0084

Address

7-7 Nibancho, Chiyoda-ku, Tokyo, Japan

TEL

03-3261-0401

Email

y-seki@mcube.jp


Public contact

Name of contact person

1st name Yosuke
Middle name
Last name Seki

Organization

Yotsuya Medical Cube

Division name

Weight Loss and Metabolic Surgery Center

Zip code

102-0084

Address

7-7 Nibancho, Chiyoda-ku, Tokyo, Japan

TEL

03-3261-0401

Homepage URL


Email

y-seki@mcube.jp


Sponsor or person

Institute

Weight Loss and Metabolic Surgery Center, Yotsuya Medical Cube

Institute

Department

Personal name



Funding Source

Organization

Daiwa Securities Health Foundation, Medtronic

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Division of Clinical Research, Yotsuya Medical Cube

Address

7-7 Nibancho, Chiyoda-ku, Tokyo, Japan

Tel

03-3261-0401

Email

h-satoh@mcube.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 11 Month 01 Day

Date of IRB

2019 Year 10 Month 30 Day

Anticipated trial start date

2019 Year 12 Month 01 Day

Last follow-up date

2023 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 10 Month 29 Day

Last modified on

2020 Year 04 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043792


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name